Vertex Pharmaceuticals Incorporated (VX1.F)
| Previous close | 411.30 |
| Open | 411.50 |
| Bid | 411.45 x 10000 |
| Ask | 414.85 x 10000 |
| Day's range | 411.50 - 411.50 |
| 52-week range | 299.75 - 420.95 |
| Volume | |
| Avg. volume | 53 |
| Market cap | 106.446B |
| Beta (5Y monthly) | 0.39 |
| PE ratio (TTM) | 29.00 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Vertex to Participate in Upcoming June Investor Conferences
BOSTON, May 22, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences.
- Business Wire
Jennifer Schneider Elected to Vertex Board of Directors
BOSTON, May 15, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Jennifer Schneider, M.D., M.S., has been elected to its Board of Directors as an independent director. Dr. Schneider has more than two decades of experience in the health care industry as a physician, scientist and health care executive. She co-founded and serves as Chief Executive Officer of Homeward Health, a company committed to rearchitecting the delivery of health and care for nearly 60 million Ame
- Business Wire
Vertex Reports First Quarter 2024 Financial Results
BOSTON, May 06, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2024, and reiterated full year 2024 financial guidance.
